Vivian Crowe
Admission Snapshot
Chief Complaint
“My head is pounding, my neck hurts when I move, and the light makes me want to throw up.”
Vivian presents with an increasingly severe headache, fever, neck stiffness, photophobia, and repeated vomiting that began before tonight’s Halloween event. Her roommate reports that she became unusually quiet and had difficulty walking out of the attraction.
Patient Profile
DOB: 08/12/2002
5 ft 6 in (167.6 cm) • 141 lb (64 kg) • BMI 22.8
Admission Isolation Status: Droplet + Standard Precautions for suspected meningococcal disease. Subsequent isolation changes are documented in the timestamp orders.
Medical History
- Occasional tension headaches; no migraine diagnosis.
- No prior meningitis, seizures, or neurologic surgery.
- No known immune deficiency or splenectomy.
- No chronic kidney, liver, or cardiac disease.
- Meningococcal vaccination records unavailable at admission; patient recalls a vaccine before college.
Home Medications
- No daily prescription medications.
- Acetaminophen 500 mg PO once at 1700 — headache; no meaningful relief.
- No recent antibiotics or immunosuppressants.
Recent History
Vivian is a graduate student living in a residence hall. She developed headache, fatigue, and chills this morning but attended a Halloween escape experience called The Last Wake with her roommate, June.
Guests were led through a chapel lined with sealed coffins. A recording whispered their names while a bell sounded beneath the floor. In the final room, each guest lay briefly inside an open coffin while an actor delivered a mock eulogy.
When the lid above Vivian began to lower, she begged them to stop because her head hurt and she needed to vomit. The actor continued reading until June realized Vivian was crying rather than playing along. Staff opened the coffin and found her shaking, shielding her eyes, and struggling to sit upright.
During the drive to the ED, Vivian asked June to turn off the dashboard lights and said she could still hear the bell. This is documented as a patient-reported experience, not confirmation of an external sound. Symptoms began before the event; the source and timing of infection are unknown.
Emergency Contact
Elena Crowe • Mother
589-216-XXXX
Insurance
University-sponsored student health insurance
Current Care Status
Admission snapshot: 10/25/2026, Emergency Department, ED-6. Evaluation for suspected bacterial meningitis is underway. Full Code; Droplet + Standard Precautions.
The timestamps document subsequent changes in location, diagnosis, isolation, and treatment.
Vivian arrives shielding her eyes and holding her neck rigid. Her roommate thinks the attraction triggered a panic attack; review the clinical findings before accepting that explanation.
Chief Concern
“My head hurts worse than any headache I’ve had. My neck is stiff, and I keep throwing up.”
History of Present Illness
Twenty-four-year-old woman with approximately 12 hours of progressive headache, fatigue, and chills, followed by neck stiffness, photophobia, and three episodes of vomiting. Symptoms preceded attendance at a Halloween attraction. Headache worsened gradually rather than reaching maximal intensity instantly. No head trauma, seizure, focal weakness, or recent antibiotic use. Roommate reports difficulty leaving the event but no loss of consciousness. Patient is currently oriented and provides a coherent history.
Past Medical History / Allergies
- Occasional tension headaches.
- No seizure disorder, prior meningitis, or neurologic surgery.
- No known immunosuppression or splenectomy.
- No known drug allergies.
- Acetaminophen 500 mg taken at 1700.
Family History
- Mother has migraine headaches.
- No known inherited immune deficiency.
Social History
- Graduate student living in a shared residence-hall room.
- No tobacco or recreational drug use.
- No alcohol tonight.
- Vaccination records requested; exact meningococcal coverage unknown.
Review of Systems
Positive for fever, severe headache, neck stiffness, photophobia, nausea, and vomiting. Denies cough, chest pain, dyspnea, dysuria, focal weakness, or known rash.
Physical Examination
Ill-appearing, eyes closed against light but opens them to voice. GCS 15; oriented x4. Temperature 39.1°C, HR 118, BP 116/72, RR 22. Pupils equal and reactive, speech clear, strength symmetric, no focal deficit. Marked discomfort with neck flexion; neck not forcibly manipulated. No papilledema appreciated on limited bedside examination. Lungs clear; regular tachycardia. Abdomen soft. No petechiae or purpura on complete initial skin examination. Capillary refill 2 seconds.
Labs
Blood collected 2105: WBC 18.6 ×10³/µL, platelets 198 ×10³/µL, sodium 134 mEq/L, creatinine 0.8 mg/dL, lactate 2.4 mmol/L, INR 1.0. Blood cultures pending. Serum pregnancy test negative. Serum glucose collected with LP at 2108: 112 mg/dL; fasting status not established.
Diagnostics
LP completed 2108 after procedural safety assessment. Opening pressure 28 cm H₂O; CSF cloudy. Early CSF results: WBC 1,850 cells/µL with 92% neutrophils, glucose 24 mg/dL, protein 190 mg/dL. CSF/serum glucose ratio approximately 0.21. Gram stain, culture, and molecular panel pending. No routine pre-LP CT obtained because no current indication was identified.
Assessment
Acute bacterial meningitis strongly suspected from presentation and inflammatory CSF profile. Organism not yet established; meningococcal disease remains a concern. Initial airway and hemodynamics stable. The frightening setting does not explain fever, meningismus, or CSF abnormalities.
Plan
- Immediate empiric meningitis-dose antibiotics.
- Adjunctive dexamethasone with the first antibiotic dose while organism is unknown; reassess with results.
- Droplet + Standard Precautions.
- Frequent neurologic, perfusion, and skin assessment.
- IV fluids and symptom management; initially NPO during vomiting.
- Infectious-disease consultation and monitored admission.
Provider Information
Dr. Zoe Langston, MD • Emergency Medicine
Patient brought by roommate, wearing a black funeral veil. Requests lights be dimmed and states, “Please don’t make me lie in the dark again.” Explained hospital setting, removed veil with permission, and maintained adequate light for safe assessment. Oriented x4, follows commands, pupils equal and reactive, no focal weakness. Headache 9/10 and pain with neck movement. Fever and tachycardia present; lungs clear, room-air SpO₂ 98%. Full skin examination without rash. Droplet signage placed; patient masked for necessary transport as tolerated. Two IVs inserted, sites clean, dry, and patent. Cultures collected 2105. Assisted with LP at 2108; site dressing dry without leakage.
Ondansetron given 2110, dexamethasone 2113, ceftriaxone started 2115, and vancomycin started 2120. Saline bolus and IV acetaminophen administered as ordered. No further vomiting during this interval. Patient reports bell-like ringing; documented as a reported symptom and communicated to provider. Roommate’s assumption of panic discussed without dismissing concern. Mother updated with patient consent.
Consultant
Dr. Kevin Morales, MD • Infectious Disease
Impression
Acute bacterial meningitis; organism pending. Residence-hall living is relevant exposure context but does not establish the source.
Recommendations
Continue empiric ceftriaxone and vancomycin. Reassess dexamethasone when organism is identified. Continue Droplet Precautions. Escalate immediately for hypotension, altered cognition, seizure, or new nonblanching rash.
| Order Type | Order Details | Priority | Ordered By | Status | Comments |
|---|---|---|---|---|---|
| Admission | Monitored inpatient admission for suspected bacterial meningitis. | Urgent | Dr. Zoe Langston, MD | In Progress | Continue ED monitoring pending bed assignment; escalate with deterioration. |
| Medication | Ceftriaxone 2 g IV q12h over 30 minutes for suspected bacterial meningitis; duration pending organism and ID review. | Stat | Dr. Zoe Langston, MD | Active | First dose started 2115. Do not mix or co-infuse with calcium-containing IV fluids. |
| Medication | Vancomycin 1,500 mg IV loading dose once over at least 2 hours; subsequent dosing by pharmacy. | Stat | Dr. Zoe Langston, MD | In Progress | Started 2120 for empiric resistant pneumococcal coverage; monitor renal function and infusion reaction. |
| Medication | Dexamethasone 10 mg IV q6h, provisional maximum 4 days, with immediate organism-guided review. | Stat | Dr. Zoe Langston, MD | Active | First dose 2113 before ceftriaxone; reassess continuation with microbiology and ID. |
| IV Fluids | 0.9% sodium chloride 500 mL IV over 30 minutes once for vomiting and reduced intake. | Urgent | Dr. Zoe Langston, MD | Completed | Completed 2140; reassess perfusion and lung sounds. |
| Medication | Ondansetron 4 mg IV q8h PRN nausea/vomiting for 24 hours. | Routine | Dr. Zoe Langston, MD | Active | Given 2110; next PRN dose no earlier than 0510. |
| Medication | Acetaminophen 1,000 mg IV over 15 minutes q8h PRN fever/headache for 24 hours. | Routine | Dr. Zoe Langston, MD | Active | First hospital dose 2130. Maximum 3,000 mg in rolling 24 hours from all sources, including home dose. |
| Isolation | Droplet + Standard Precautions; private room. | Stat | Dr. Zoe Langston, MD | Active | If meningococcal disease confirmed, continue until at least 24 hours of effective therapy and infection-prevention review. |
| Monitoring | Continuous ECG; vital signs and neurologic checks q15 min initially; assess skin for petechiae/purpura. | Urgent | Dr. Zoe Langston, MD | Active | Report altered cognition, seizure, hypotension, pupillary change, or rash immediately. |
| Laboratory | CBC, BMP, lactate, INR/aPTT, pregnancy test, blood cultures ×2; repeat lactate within 2 hours. | Stat | Dr. Zoe Langston, MD | Active | Initial samples collected 2105; cultures pending. |
| Procedure / Tests | LP with opening pressure, cell count/differential, protein, glucose, Gram stain, culture, molecular panel; paired serum glucose. | Stat | Dr. Zoe Langston, MD | Completed / Results Pending | LP completed 2108 before antibiotics; microbiology pending. |
| Diet / Safety | NPO initially during vomiting; aspiration, seizure, and fall precautions; assisted mobility. | Urgent | Dr. Zoe Langston, MD | Active | Reassess intake after stabilization. |
| Consult | Infectious-disease consultation. | Urgent | Dr. Zoe Langston, MD | Completed | Dr. Morales evaluated 2140; follow-up ongoing. |
| Vital Sign | 2100 | Reference / Target |
|---|---|---|
| Temperature | 39.1°C / 102.4°F | 36.1–37.2°C / 97–99°F |
| Heart Rate | 118 bpm | 60–100 bpm |
| Respiratory Rate | 22/min | 12–20/min |
| Blood Pressure | 116/72 mmHg | Resting reference <120/<80; assess perfusion |
| MAP | Approximately 87 mmHg | Interpret with perfusion; subsequent shock target ≥65 |
| SpO₂ | 98% room air | 95–100% |
| Pain | 9/10 headache | 0–10 subjective scale |
| GCS | 15 | 15 |
| Urine Output | Not measured | Generally ≥0.5 mL/kg/hr; approximately 32 mL/hr |
Blood specimens collected 2105 unless otherwise labeled. H/L flags follow NSJH teaching intervals. Glucose uses the standard fasting reference of 60–100 mg/dL; fasting status was not established. H* does not diagnose diabetes.
| Lab Test | Result | Reference Range |
|---|---|---|
| WBC | 18.6 H | 5.0–11.0 ×10³/µL |
| Hemoglobin | 12.8 | 12.0–15.0 g/dL, female |
| Platelets | 198 | 150–450 ×10³/µL |
| Sodium | 134 L | 135–145 mEq/L |
| Potassium | 3.8 | 3.5–5.0 mEq/L |
| Bicarbonate | 22 | 22–29 mEq/L |
| BUN | 14 | 10–20 mg/dL |
| Creatinine | 0.8 | 0.6–1.2 mg/dL |
| Serum Glucose, paired at 2108 | 112 H* | 60–100 mg/dL, fasting reference* |
| Lactate | 2.4 H | 0.5–2.2 mmol/L |
| INR | 1.0 | 0.9–1.2, not anticoagulated |
| aPTT | 29 | 20–45 seconds |
| Serum hCG | Negative | Negative |
| Blood Cultures ×2 | Pending | No growth |
| CSF Test | Result | Reference Range |
|---|---|---|
| Appearance | Cloudy | Clear |
| Opening Pressure | 28 H | Approximately 10–25 cm H₂O in adults |
| WBC | 1,850 H | 0–5 cells/µL |
| Neutrophils | 92% | No neutrophilic predominance expected |
| Glucose | 24 L | 40–70 mg/dL; interpret with paired serum |
| CSF / Serum Glucose Ratio | 0.21 L | Usually approximately 0.6 |
| Protein | 190 H | 15–45 mg/dL |
| Gram Stain | Pending | No organisms seen |
| Molecular Panel / Culture | Pending | No pathogen detected / no growth |
- LP — Completed 2108 without immediate complication; cloudy CSF and inflammatory profile.
- CSF Gram stain, molecular panel, and culture — Pending.
- CT head — Not ordered initially; no identified indication for routine pre-LP imaging.
- Telemetry — Sinus tachycardia.
- Blood cultures — Collected before antibiotics; pending.
- 2100 — Arrival; Droplet Precautions initiated.
- 2105 — Blood specimens and cultures collected.
- 2108 — LP and paired serum glucose obtained.
- 2110 — Ondansetron administered.
- 2113 — Dexamethasone administered.
- 2115 — Ceftriaxone started.
- 2120 — Vancomycin loading infusion started.
- 2130 — IV acetaminophen administered.
- 2140 — Saline bolus completed; ID consultation documented.
Review Vivian’s presentation and CSF findings before answering both questions.
Fever, progressive headache, neck stiffness, vomiting, and photophobia require urgent assessment for infection. Panic does not explain the markedly elevated CSF white-cell count, neutrophilic predominance, low glucose ratio, and high protein. These findings support a bacterial inflammatory process involving the meninges. Continue ordered treatment and reassess neurologic and circulatory status rather than attributing illness to the attraction alone.
Reassuring findings at one examination do not exclude evolving invasive infection. Record the absence of rash and baseline cognition, then compare subsequent examinations. New nonblanching lesions, falling BP, delayed capillary refill, reduced urine output, or altered cognition require escalation. Anticipate deterioration rather than waiting for every classic feature to appear before taking action.
Purple spots appear beneath Vivian’s costume sleeves and do not blanch. The pathogen has been identified, but her perfusion and coagulation trends now require urgent attention.
Chief Concern
“I’m cold, my head still hurts, and I feel like I’m going to faint.”
Interval History
At 2210, developed hypotension, slowed responses, and new nonblanching petechiae over legs and forearms. Transferred to ICU at 2230. Additional 1,500 mL saline given in reassessed boluses, bringing total initial crystalloid to 2,000 mL, approximately 31 mL/kg, by 2250. Persistent hypotension required norepinephrine at 2255. At 2302, BP was 100/60 with MAP approximately 73 on norepinephrine, supporting monitored CT transport. CT completed 2308 with monitoring and vasopressor maintained throughout transport.
At 2330, BP decreased to 88/52, with arterial MAP 64 on norepinephrine 0.08 mcg/kg/min. Measurement and infusion delivery checked; rate increased to 0.10 mcg/kg/min at 2332 under the titration order. MAP improved to 69 at 2335. CSF molecular panel reported N. meningitidis at 2300; Gram stain shows gram-negative diplococci. Vancomycin loading dose completed 2320; maintenance canceled after ID review. Dexamethasone discontinued before the next scheduled dose.
Relevant History / Allergies
- No known drug allergies or immune deficiency.
- Residence-hall roommate and close-contact history under review.
- No anticoagulant use.
Review of Systems
Persistent headache, photophobia, weakness, chills, and dizziness. Responses slowed; follows commands. No witnessed seizure. Denies chest pain.
Physical Examination
At 2330: temperature 39.5°C, HR 136, RR 28, BP 88/52, arterial MAP 64. GCS 14, confused about date; airway protected. Pupils equal and reactive, strength symmetric. SpO₂ 96% room air; lungs clear. Scattered nonblanching petechiae and small purpuric lesions on forearms and lower legs. Extremities cool; capillary refill 4 seconds. No active mucosal bleeding or expanding line-site hematoma.
Labs
2300: lactate 5.1 mmol/L, platelets 72 ×10³/µL, INR 1.8, aPTT 46 seconds, fibrinogen 130 mg/dL, D-dimer 6,200 ng/mL FEU, creatinine 1.3 mg/dL, bicarbonate 18 mEq/L. Pattern concerning for consumptive coagulopathy. Blood cultures remain pending.
Diagnostics
CSF molecular testing confirms N. meningitidis. CT at 2308 after documented hemodynamic improvement: no hemorrhage, mass effect, or hydrocephalus. Imaging obtained for sustained decline in cognition. Normal CT does not replace neurologic reassessment. Repeat LP not planned during shock and coagulopathy.
Assessment
Confirmed meningococcal meningitis with suspected meningococcemia, septic shock, evolving acute kidney injury, and findings concerning for disseminated intravascular coagulation. MAP at 2330 was below the ordered ≥65 target; reassessment and titration produced improvement. Continued ICU surveillance required.
Plan
- Continue ceftriaxone at meningitis dosing.
- Titrate norepinephrine to the ordered MAP target while assessing overall perfusion.
- Serial neurologic, skin, bleeding, and distal-perfusion assessments.
- Follow urine output and laboratory trends.
- Reassess bleeding and procedural needs before blood-product decisions.
- Continue Droplet Precautions and public-health contact management.
Provider Information
Dr. Joaquin Reyes, DO • Critical Care
Transferred to ICU after hypotension and new rash. Earlier stated, “Those weren’t there when I got dressed.” Forearm and lower-leg petechiae do not blanch; distribution documented under adequate lighting. Intermittently asks whether the coffin lid is still above her; calmly reoriented. GCS 14, pupils equal and reactive, follows commands, no seizure or focal weakness observed. Headache 8/10. Foley inserted 2235 using sterile technique for hourly output; 20 mL during preceding hour. Left radial arterial line inserted 2245, dressing dry.
Norepinephrine started 2255 via dedicated proximal IV; site without swelling, blanching, or leakage. At 2302, BP 100/60, MAP approximately 73. CT transport completed with clinical escort, monitoring, and uninterrupted infusion. At 2330, cuff BP 88/52 and arterial MAP 64. Transducer level, waveform, and infusion delivery checked. Dr. Reyes notified of below-target MAP and oliguria. Norepinephrine increased from 0.08 to 0.10 mcg/kg/min at 2332 under order; MAP 69 at 2335. Second IV patent. Lungs clear, room-air SpO₂ 96%. LP dressing dry; no active gum, urinary, or puncture-site bleeding. Mother updated. June reports sharing drinks during the preceding week and has been referred for close-contact evaluation. Droplet Precautions maintained.
Consultant
Dr. Kevin Morales, MD • Infectious Disease
Impression
Confirmed meningococcal meningitis with shock and probable bloodstream involvement. Molecular result and Gram stain support pathogen-directed treatment.
Recommendations
Continue ceftriaxone. Stop vancomycin maintenance and adjunctive dexamethasone. Provisional seven-day course, reassessed with recovery and culture results. Notify public health through the clinical team. Infection prevention to assess qualifying contacts and facilitate prompt prophylaxis through their own clinicians. Attendance at the attraction alone does not establish a qualifying exposure.
| Order Type | Order Details | Priority | Ordered By | Status | Comments |
|---|---|---|---|---|---|
| Admission | ICU care for meningococcal meningitis with septic shock. | Stat | Dr. Joaquin Reyes, DO | Active | Supersedes initial monitored-floor plan. |
| Medication | Ceftriaxone 2 g IV q12h over 30 minutes; provisional seven-day course from first dose, reassessed by ID. | Urgent | Dr. Kevin Morales, MD | Active | First dose 2115; next 0915. Do not mix or co-infuse with calcium-containing solutions. |
| Medication | Norepinephrine IV continuous infusion; titrate by 0.02 mcg/kg/min q2–5 min to MAP ≥65; range 0.02–0.5 mcg/kg/min pending reassessment. | Stat | Dr. Joaquin Reyes, DO | Active | Started 2255. Rate 0.08 at 2330; increased to 0.10 at 2332. Dedicated proximal IV with frequent checks; notify provider for escalating requirements. |
| IV Fluids | 0.9% sodium chloride boluses totaling 2,000 mL. | Stat | Dr. Joaquin Reyes, DO | Completed | Approximately 31 mL/kg. Completed 2250; additional fluid guided by reassessment. |
| Medication | Vancomycin loading dose and planned maintenance therapy. | Routine | Dr. Kevin Morales, MD | Discontinued | Loading dose completed 2320; maintenance canceled after organism identification. |
| Medication | Dexamethasone 10 mg IV q6h. | Routine | Dr. Kevin Morales, MD | Discontinued | Only initial dose administered; stopped after organism-specific review. |
| Medication | Acetaminophen 1,000 mg IV q8h PRN fever/headache through 10/26 at 2130. | Routine | Dr. Joaquin Reyes, DO | Active | Last 2130; next no earlier than 0530. Maximum 3,000 mg in rolling 24 hours from all sources, including home dose. |
| Medication | Ondansetron 4 mg IV q8h PRN nausea/vomiting through 10/26 at 2110. | Routine | Dr. Joaquin Reyes, DO | Active | Last 2110; next no earlier than 0510. |
| Isolation | Droplet + Standard Precautions until at least 24 hours of effective therapy and infection-prevention review. | Urgent | Dr. Joaquin Reyes, DO | Active | Earliest discontinuation consideration: 10/26 after 2115. |
| Procedure / Monitoring | Radial arterial line for continuous BP during shock; reassess need daily. | Urgent | Dr. Joaquin Reyes, DO | Insertion Completed; Monitoring Active | Inserted 2245. Check leveling, waveform, site, and distal perfusion. |
| GU | Foley for hourly urine output during shock; reassess need daily. | Urgent | Dr. Joaquin Reyes, DO | Active | Inserted 2235. Report output below approximately 32 mL/hr with clinical context. |
| Monitoring | Continuous ECG/BP; neurologic checks q15 min initially; skin, bleeding, and distal-perfusion checks q1h. | Stat | Dr. Joaquin Reyes, DO | Active | Report new focal deficit, seizure, bleeding, expanding purpura, or cool painful digits. |
| Laboratory | CBC, BMP, lactate, INR/aPTT, fibrinogen q4h initially; follow blood and CSF cultures. | Urgent | Dr. Joaquin Reyes, DO | Active | 2300 results reviewed; frequency reassessed with recovery. |
| Diagnostics | CT head without contrast for sustained decline in cognition, after stabilization sufficient for transport. | Urgent | Dr. Joaquin Reyes, DO | Completed | Completed 2308 with monitoring and vasopressor maintained. No repeat LP during shock/coagulopathy. |
| Diet / Safety | NPO during shock; aspiration, seizure, and fall precautions. | Urgent | Dr. Joaquin Reyes, DO | Active | Reassess feeding after stabilization. |
| VTE Prevention | Mechanical prophylaxis after limb-perfusion assessment; pharmacologic prophylaxis held during evolving coagulopathy. | Routine | Dr. Joaquin Reyes, DO | Active | Reassess bleeding and thrombosis risk daily. |
| Public Health | Notify public health; assess close contacts and occupational secretion exposures. | Urgent | Dr. Kevin Morales, MD | In Progress | Contact prophylaxis requires separate evaluation and orders. |
| Vital Sign | 2100 | 2330 | Reference / Target |
|---|---|---|---|
| Temperature | 39.1°C / 102.4°F | 39.5°C / 103.1°F | 36.1–37.2°C / 97–99°F |
| Heart Rate | 118 | 136 | 60–100 bpm |
| Respiratory Rate | 22 | 28 | 12–20/min |
| Blood Pressure | 116/72 | 88/52 on norepinephrine 0.08 mcg/kg/min | mmHg; assess perfusion |
| MAP | Approximately 87 | 64; improved to 69 at 2335 after titration | Ordered target ≥65 mmHg |
| SpO₂ | 98% room air | 96% room air | 95–100% |
| Pain | 9/10 headache | 8/10 headache | 0–10 subjective scale |
| GCS | 15 | 14 | 15 |
| Urine Output | Not measured | 20 mL in preceding hour | Generally ≥32 mL/hr at 64 kg |
Blood columns show collection times. H/L flags follow NSJH teaching intervals. Glucose reference is fasting; fasting status was not established. Interpret H* in context. CSF updates refer to the original 2108 specimen, not a second LP.
| Lab Test | 2105 | 2300 | Reference Range |
|---|---|---|---|
| WBC | 18.6 H | 24.8 H | 5.0–11.0 ×10³/µL |
| Hemoglobin | 12.8 | 11.4 L | 12.0–15.0 g/dL, female |
| Platelets | 198 | 72 L | 150–450 ×10³/µL |
| Sodium | 134 L | 132 L | 135–145 mEq/L |
| Potassium | 3.8 | 4.2 | 3.5–5.0 mEq/L |
| Bicarbonate | 22 | 18 L | 22–29 mEq/L |
| BUN | 14 | 24 H | 10–20 mg/dL |
| Creatinine | 0.8 | 1.3 H | 0.6–1.2 mg/dL |
| Glucose | 112 H*, paired at 2108 | 156 H* | 60–100 mg/dL, fasting reference* |
| Lactate | 2.4 H | 5.1 H | 0.5–2.2 mmol/L |
| INR | 1.0 | 1.8 H | 0.9–1.2 |
| aPTT | 29 | 46 H | 20–45 seconds |
| Fibrinogen | Not obtained | 130 L | 203–377 mg/dL |
| D-dimer | Not obtained | 6,200 H | <500 ng/mL FEU |
| Blood Cultures | Pending | Pending | No growth |
| Test | Original Result | Update by 2330 | Reference Range |
|---|---|---|---|
| WBC / Differential | 1,850; 92% neutrophils | Not repeated | 0–5 cells/µL |
| Glucose / Serum Ratio | 24 mg/dL / 0.21 | Not repeated | 40–70 mg/dL; ratio approximately 0.6 |
| Protein | 190 H | Not repeated | 15–45 mg/dL |
| Gram Stain | Pending | Gram-negative diplococci | No organisms seen |
| Molecular Panel | Pending | N. meningitidis detected | No pathogen detected |
| Culture / Susceptibility | Pending | Pending | No growth |
- CSF molecular panel — Final at 2300: N. meningitidis detected.
- CSF Gram stain — Gram-negative diplococci; culture pending.
- CT head — Completed 2308 after BP improved to 100/60 at 2302 on norepinephrine. No hemorrhage, mass effect, or hydrocephalus.
- Repeat LP — Not ordered during shock and coagulopathy.
- Blood cultures — Pending; bloodstream involvement suspected.
- Telemetry — Sinus tachycardia without sustained dysrhythmia.
- 2210 — Nonblanching rash, hypotension, and slowed responses identified.
- 2230 — ICU transfer completed.
- 2235 — Foley inserted for hourly urine output.
- 2245 — Left radial arterial line inserted.
- 2250 — Total crystalloid reached 2,000 mL; hypotension persisted.
- 2255 — Norepinephrine started.
- 2300 — Repeat blood specimens collected; CSF molecular result reported.
- 2302 — BP 100/60, MAP approximately 73; monitored CT transport approved.
- 2308 — CT completed with vasopressor and monitoring maintained.
- 2310 — ID updated antimicrobial and contact-management plan.
- 2320 — Vancomycin loading dose completed.
- 2330 — BP 88/52 and arterial MAP 64 on norepinephrine 0.08; delivery and measurement reassessed.
- 2332 — Norepinephrine increased to 0.10 mcg/kg/min under order.
- 2335 — MAP improved to 69; perfusion assessment continued.
Compare hemodynamic, organ-perfusion, and coagulation trends.
Estimated MAP is (88 + 2 × 52) ÷ 3 = 64 mmHg, matching the arterial reading and falling below this patient's ordered target. Check the measurement, arterial-line leveling and waveform, IV site, infusion concentration, pump settings, and delivery. Follow the titration order and reassess promptly; increasing the rate to 0.10 at 2332 produces MAP 69 at 2335. Continue evaluating cognition, capillary refill, urine output, and lactate trajectory rather than treating one number as proof of restored perfusion. A brief value of 64 does not alone establish a new injury, but oliguria and other shock findings make the overall assessment clinically important.
This pattern raises concern for disseminated intravascular coagulation. Widespread coagulation activation can consume platelets and clotting factors while producing small-vessel thrombosis, so bleeding and ischemia may coexist. Assess mucosa, urine, puncture sites, skin progression, and distal color, warmth, pain, sensation, and perfusion. Report bleeding, expanding purpura, painful cool digits, or worsening organ function immediately. Minimize unnecessary invasive procedures and follow clinician-directed blood-product decisions while continuing treatment of the underlying infection.
Vivian is alert and hemodynamically stable, but voices sound muffled in her left ear. Review the remaining treatment, complication assessment, and contact-management needs.
Chief Concern
“My headache is much better, but everyone sounds muffled on my left side. Is my hearing going to come back?”
Interval History
Continued improvement on ceftriaxone. Norepinephrine discontinued 10/26 at 1200 without recurrent hypotension. Droplet Precautions discontinued after infection-prevention review at 2200 on 10/26, more than 24 hours after effective therapy began. Transferred to step down this morning. Awake, oriented, eating, and mobilizing with assistance. Headache 2/10.
Reports left-sided muffled hearing and intermittent tinnitus, now easier to describe after recovery from confusion. Earlier bell-like symptom is relevant history but does not by itself establish its cause. Formal audiology pending.
Relevant History / Allergies
- No previous hearing deficit reported by patient or mother.
- No known drug allergies.
- No seizure during hospitalization.
Review of Systems
Mild headache, fatigue, left-sided hearing change, and tinnitus. Denies vomiting, dizziness at rest, chest pain, dyspnea, new weakness, or active bleeding.
Physical Examination
Alert and oriented x4, GCS 15. Temperature 37.2°C, HR 82, BP 114/70, RR 16, room-air SpO₂ 99%. Pupils equal and reactive; strength symmetric. Neck discomfort improved. Ear canals clear; tympanic membranes without obvious effusion. Bedside response to soft speech reduced on the left. Hearing-loss type, severity, and prognosis not established. Petechiae fading without new purpura, necrosis, or distal ischemia. Extremities warm.
Labs
0800: WBC 12.9 ×10³/µL, platelets 118 ×10³/µL, INR 1.2, fibrinogen 260 mg/dL, creatinine 0.9 mg/dL. Latest lactate 1.4 mmol/L collected 10/26 at 1600; not repeated this morning. Blood and CSF cultures identify ceftriaxone-susceptible N. meningitidis.
Diagnostics
Audiology requested for unilateral hearing symptoms. Prior CT at 2308 on 10/25 showed no hemorrhage, mass effect, or hydrocephalus. No repeat LP indicated in the current improving course. No seizure or focal deficit observed.
Assessment
Meningococcal meningitis and bacteremia with resolved septic shock. Kidney function and coagulation improving; thrombocytopenia not fully resolved. New auditory symptoms require assessment for a post-meningitis complication. Improved vital signs do not establish complete recovery.
Plan
- Complete ceftriaxone course under ID oversight.
- Audiology before discharge when feasible; specialist referral according to findings.
- Continue neurologic, mobility, skin, and bleeding assessments.
- Advance activity with assistance and assess tolerance.
- Confirm contact management and vaccination review.
- Arrange recovery support, follow-up, and written return precautions.
Provider Information
Dr. Priya Desai, MD • Internal Medicine
Arrived from ICU awake and oriented x4. States, “When they said my name in that room, I thought it was part of the show. Now I’m scared I won’t hear normally again.” Acknowledged concern and explained pending testing without predicting recovery. Face-to-face communication used in quiet setting; patient prefers speaker on right side. Headache 2/10, no vomiting. Pupils equal and reactive, strength symmetric. Ate breakfast without difficulty. Assisted to chair without dizziness; fatigue limits walking. Lungs clear, room-air SpO₂ 99%. Petechiae fading without new lesions or bleeding.
Peripheral IV clean, dry, and patent. Foley removed 10/26 at 1700 and arterial line removed at 1730 after stabilization; former sites dry. Voiding spontaneously, 300 mL measured over preceding six hours. Mother included in teaching with consent. June’s prophylaxis confirmed by infection prevention; other qualifying contacts followed through public health. Audiology pending. Patient remains hospitalized for treatment and assessment; no discharge order.
Consultant
Dr. Kevin Morales, MD • Infectious Disease
Interval Assessment
CSF and blood cultures confirm ceftriaxone-susceptible N. meningitidis. Shock resolved; no new skin progression. Continue ceftriaxone with provisional seven-day duration, reassessed for complications or delayed recovery.
Recommendations
Hearing assessment and structured follow-up remain important. Infection prevention confirms close-contact investigation underway. Review vaccination history with public health; vaccination does not replace indicated exposure prophylaxis.
| Order Type | Order Details | Priority | Ordered By | Status | Comments |
|---|---|---|---|---|---|
| Disposition | Neurologic step-down care; discharge planning after treatment and complication assessment. | Routine | Dr. Priya Desai, MD | Active | Room 318; no discharge order. |
| Medication | Ceftriaxone 2 g IV q12h over 30 minutes; provisional seven-day course starting 10/25 at 2115. | Urgent | Dr. Kevin Morales, MD | Active | 0915/2115 schedule. Planned 14 doses if unchanged; final scheduled dose 11/01 at 0915. ID confirms duration. Do not mix or co-infuse with calcium-containing solutions. |
| Medication | Acetaminophen 650 mg PO q6h PRN headache/fever through discharge or 72 hours, then reassess. | Routine | Dr. Priya Desai, MD | Active | Replaces expired IV order; maximum 3,000 mg/24 hours from all sources. |
| Medication | Enoxaparin 40 mg subcutaneous daily for inpatient VTE prophylaxis after bleeding-risk review. | Routine | Dr. Priya Desai, MD | Active | Hold and notify provider for active bleeding or platelets <100 ×10³/µL per this order. Reassess renal dosing if function worsens. |
| Medication | Norepinephrine infusion. | Routine | Dr. Joaquin Reyes, DO | Discontinued | Stopped 10/26 at 1200; no recurrent shock. |
| Medication | Vancomycin and dexamethasone. | Routine | Dr. Kevin Morales, MD | Discontinued | Stopped after organism identification; not restarted. |
| Medication | Initial IV acetaminophen and ondansetron PRN orders. | Routine | Dr. Priya Desai, MD | Expired | Initial 24-hour orders ended. |
| Isolation | Standard Precautions. | Routine | Dr. Priya Desai, MD | Active | Droplet Precautions ended 10/26 at 2200 after review and more than 24 hours of effective therapy. |
| Monitoring | Vital signs and neurologic checks q4h; skin, bleeding, and mobility assessment each shift and with change. | Routine | Dr. Priya Desai, MD | Active | Supersedes ICU frequency; escalate new confusion, severe headache, seizure, or focal deficit. |
| Laboratory | CBC/BMP tomorrow morning; coagulation studies with bleeding or deterioration. | Routine | Dr. Priya Desai, MD | Active | Platelet recovery ongoing; q4h ICU schedule discontinued. |
| Hearing Assessment | Formal audiology for left-sided muffled hearing and tinnitus; specialist referral based on results. | Urgent | Dr. Priya Desai, MD | Pending | Before discharge when feasible; type and permanence not established. |
| Diet / Activity | Regular diet as tolerated; assisted ambulation and gradual activity progression. | Routine | Dr. Priya Desai, MD | Active | NPO discontinued; evaluate fatigue and balance. |
| Devices | Maintain peripheral IV for antibiotics; monitor intake and spontaneous voiding. | Routine | Dr. Priya Desai, MD | Active | Foley removed 10/26 at 1700; arterial line removed 1730. No maintenance IV fluid with adequate intake. |
| Public Health | Complete close-contact management and vaccination-record review. | Urgent | Dr. Kevin Morales, MD | In Progress | Roommate prophylaxis confirmed; other contacts tracked separately. |
| Education / Follow-up | Written medication plan, hearing follow-up, return precautions, gradual activity plan, and clinical review. | Routine | Dr. Priya Desai, MD | In Progress | Teach-back with patient and mother; coordinate access and appointments. |
| Vital Sign | 2100 (10/25) | 2330 (10/25) | 0900 (10/27) | Reference / Target |
|---|---|---|---|---|
| Temperature | 39.1°C / 102.4°F | 39.5°C / 103.1°F | 37.2°C / 99.0°F | 36.1–37.2°C / 97–99°F |
| Heart Rate | 118 | 136 | 82 | 60–100 bpm |
| Respiratory Rate | 22 | 28 | 16 | 12–20/min |
| Blood Pressure | 116/72 | 88/52 on norepinephrine 0.08 | 114/70 off vasopressors | mmHg; assess perfusion |
| MAP | Approximately 87 | 64 at 2330; 69 at 2335 after titration | Approximately 85 | Shock-treatment target ≥65 mmHg |
| SpO₂ | 98% room air | 96% room air | 99% room air | 95–100% |
| Pain | 9/10 headache | 8/10 headache | 2/10 headache | 0–10 subjective scale |
| GCS | 15 | 14 | 15 | 15 |
| Urine Output | Not measured | 20 mL/hr | 300 mL over preceding 6 hours; approximately 50 mL/hr | Generally ≥32 mL/hr at 64 kg |
Final column contains 0800 results unless otherwise labeled. H/L flags follow NSJH teaching intervals. Glucose uses the standard fasting interval; prior specimens were not confirmed fasting. H* does not diagnose diabetes. No repeat CSF specimen was collected.
| Lab Test | 2105 (10/25) | 2300 (10/25) | Latest at 0900 (10/27) | Reference Range |
|---|---|---|---|---|
| WBC | 18.6 H | 24.8 H | 12.9 H | 5.0–11.0 ×10³/µL |
| Hemoglobin | 12.8 | 11.4 L | 11.2 L | 12.0–15.0 g/dL, female |
| Platelets | 198 | 72 L | 118 L | 150–450 ×10³/µL |
| Sodium | 134 L | 132 L | 137 | 135–145 mEq/L |
| Potassium | 3.8 | 4.2 | 3.9 | 3.5–5.0 mEq/L |
| Bicarbonate | 22 | 18 L | 24 | 22–29 mEq/L |
| BUN | 14 | 24 H | 17 | 10–20 mg/dL |
| Creatinine | 0.8 | 1.3 H | 0.9 | 0.6–1.2 mg/dL |
| Glucose | 112 H*, paired at 2108 | 156 H* | 96 | 60–100 mg/dL, fasting reference* |
| Lactate | 2.4 H | 5.1 H | 1.4 from 10/26 at 1600; not repeated today | 0.5–2.2 mmol/L |
| INR | 1.0 | 1.8 H | 1.2 | 0.9–1.2 |
| aPTT | 29 | 46 H | 32 | 20–45 seconds |
| Fibrinogen | Not obtained | 130 L | 260 | 203–377 mg/dL |
| D-dimer | Not obtained | 6,200 H | Not repeated | <500 ng/mL FEU |
| Blood Cultures | Pending | Pending | N. meningitidis; ceftriaxone susceptible | No growth |
| Test | Initial Finding | Current Status | Reference Range |
|---|---|---|---|
| WBC / Differential | 1,850; 92% neutrophils | Not repeated | 0–5 cells/µL |
| Glucose / Serum Ratio | 24 mg/dL / 0.21 | Not repeated | 40–70 mg/dL; ratio approximately 0.6 |
| Protein | 190 H | Not repeated | 15–45 mg/dL |
| Gram Stain | Initially pending | Gram-negative diplococci | No organisms seen |
| Molecular Panel | Initially pending | N. meningitidis detected | No pathogen detected |
| Culture | Initially pending | N. meningitidis; ceftriaxone susceptible | No growth |
- CSF molecular testing and culture — N. meningitidis confirmed; ceftriaxone susceptibility reported.
- Blood cultures — N. meningitidis confirmed, establishing bacteremia.
- Audiology — Requested for left-sided hearing change; assessment and classification pending.
- CT head — Completed 10/25 at 2308 after hemodynamic improvement; no hemorrhage, mass effect, or hydrocephalus.
- Repeat LP — Not ordered in the current improving course.
- Neurologic examination — GCS 15, symmetric strength, no new focal deficit.
- 10/26, 1200 — Norepinephrine discontinued.
- 10/26, 1600 — Lactate 1.4; frequent scheduled lactate testing discontinued after review.
- 10/26, 1700 — Foley removed; spontaneous voiding monitored.
- 10/26, 1730 — Arterial line removed; site and distal perfusion reassessed.
- 10/26, 2200 — Droplet Precautions discontinued after infection-prevention review.
- 10/27, 0730 — Transferred to neurologic step down, Room 318.
- 0800 — Follow-up blood specimens collected.
- 0830 — ID follow-up; culture-directed therapy continued.
- 0900 — Hearing symptoms reassessed; audiology pending and discharge planning underway.
Review recovery, auditory symptoms, and contact management.
Resolution of shock does not exclude an auditory complication of meningitis. Document the affected side, symptom onset, tinnitus, and impact on communication, then ensure testing and follow-up are arranged. Face Vivian, reduce background noise, use her preferred speaking position, and check understanding. The earlier bell-like report is relevant history but does not prove the mechanism of the current symptom. Avoid promising recovery or labeling the loss permanent before assessment establishes type and severity.
Prophylaxis decisions depend on qualifying exposure, including household-type contact and relevant exposure to oral or respiratory secretions. Attendance at the attraction alone does not mean everyone qualifies. Vaccination history does not replace indicated chemoprophylaxis for an exposed close contact. Confirm contact management through infection prevention and public health, and verify Vivian’s antibiotic plan, hearing assessment, follow-up, and support at home. Written precautions should address recurrent fever, severe headache, confusion, seizure, weakness, or concerning rash. Use teach-back rather than assuming understanding from apparent clinical improvement.